TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01604434

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incubator-torso bag
Description: While being placed into an incubator, infant will be placed into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket over the plastic bag and will receive a cloth hat. He/she will remain in the bag for one hour.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Incubator-no plastic bag
Description: Infant will be placed in the incubator, wrapped in a blanket, with a cloth hat, according to standard protocol.
Study: NCT01654393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triage nurses applying the OAR
Description: Triage nurses applying the OAR during assessment and ordering foot/ankle x-rays as necessary.
Study: NCT03779906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isovue
Description: Isovue will be given to all subjects per the standard of clinical care.
Study: NCT01709604

Intervention type: PROCEDURE
Intervention: CVVH
Description: Ultrafiltration at 35ml/h/Kg

Intervention type: PROCEDURE
Intervention: CVVH
Description: Ultrafiltration at 35ml/h/Kg

Intervention type: PROCEDURE
Intervention: Standardized therapy regimens
Description: Standardized therapy regimens included the followings:~1. Remove all contaminated clothing~2. Gastric lavage~3. Receive activated charcoal as quickly as possible~4. Hemoperfusion with activated charcoal(160g)~5. Immunosuppression with methylprednisolone~6. Antioxidants (glutathione,1.2 gram iv twice a day)~7. Supportive care
Study: NCT06039657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SEAS training
Description: Patients who opted to participate in the SEAS group underwent SEAS therapy. The SEAS therapy program initially comrised patient education and active self-correction. Subsequently, stabilization of active self correction was tried to be performed through various functional activities. These activities were selected from everyday life examples, with increasing levels of difficulty over time. With SEAS exercises, the activation of self-correction was aimed to be increased through various activities in sitting, standing and walking conditions, with the goal of correcting scoliosis in this way

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Patients who declined or were unable to participate in outpatient exercise programs received standard care. Standard care included exercises for postural re-education, traditional strengthening and stretching exercises for one session, followed by observation for one year.
Study: NCT01508793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimize Sleep
Description: Children are asked to increase their sleep by approximately 1 1/2 hours/night for the duration of the two month intervention
Study: NCT03596255

Intervention type: DIAGNOSTIC_TEST
Intervention: Estimated level of DA
Description: the dental personnel estimated the patient's level of DA (eDA) on a 100mm VAS

Intervention type: DIAGNOSTIC_TEST
Intervention: MDAS
Description: The patient rated their DA using the Modified Dental Anxiety Scale (MDAS)
Study: NCT03634293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alirocumab Injectable Product
Description: Alirocumab is an human monoclonal antibodies directed against Proprotein convertase subtilisin/kexin type 9 (PCSK9). It is administered once every two weeks subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: The placebo will be 2 ml' of 0.9% saline injected subcutaneously.
Study: NCT02813590

Intervention type: OTHER
Intervention: Ascitic fluid puncture

Intervention type: OTHER
Intervention: Ascitic fluid puncture

Intervention type: OTHER
Intervention: Skin swaps from puncture side

Intervention type: OTHER
Intervention: Skin swaps from puncture side
Study: NCT00205881

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HiRes 90K Bionic Ear System
Description: Cochlear implant system
Study: NCT02574468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone applied on pulp or Dexamethasone did not applied on pulp
Description: on half of cases we put dexamethasone on pulp on other half we did not put dexamethasone on pulp

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone applied on pulp or Dexamethasone did not applied on pulp
Description: on half of cases we put dexamethasone on pulp on other half we did not put dexamethasone on pulp

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DPC or MP
Description: on half of cases we treat teeth with DPC(Direct Pulp Cap) on other half we treat teeth with MP(Miniature Pulpotomy)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DPC or MP
Description: on half of cases we treat teeth with DPC(Direct Pulp Cap) on other half we treat teeth with MP(Miniature Pulpotomy)
Study: NCT04968301

Intervention type: DEVICE
Intervention: ultrasound Doppler
Description: A cross-sectional study:the development of the hip joint was studied by measuring the anatomical circumference of the capsular muscle of the iliac joint with ultrasound Doppler

Intervention type: DEVICE
Intervention: ultrasound Doppler
Description: A cross-sectional study:the development of the hip joint was studied by measuring the anatomical circumference of the capsular muscle of the iliac joint with ultrasound Doppler

Intervention type: DEVICE
Intervention: ultrasound Doppler
Description: A cross-sectional study:the development of the hip joint was studied by measuring the anatomical circumference of the capsular muscle of the iliac joint with ultrasound Doppler
Study: NCT03910062

Intervention type: PROCEDURE
Intervention: Lower limb angiography via the reperfusion cannula and NIRS monitoring
Description: Data collection only (lower limb angiography, lower limbs NIRS values).
Study: NCT03240302

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICSI petri dish
Description: Half of the oocytes will be placed into the standard ICSI petri dish and they will be injected with sperm with normal morphology.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICSI petri dish
Description: Half of the oocytes will be placed into a PICSI petri dish (whose bottom is coated with hyaluronic acid) and the mature spermatozoa with CD44 receptors that are attached to the bottom of the dish will be injected into them.
Study: NCT03244215

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Corneal Confocal Imaging
Description: Retinal imaging will be ordered for all subjects in the study group. Corneal
Study: NCT02813590

Intervention type: OTHER
Intervention: Stool samples

Intervention type: OTHER
Intervention: Stool samples
Study: NCT01560104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01786434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine medication arm
Description: 50 micrograms of fentanyl given before the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl on-demand arm
Description: Fentanyl 50 microgram is provided on-demand, that is, if the patient has pain during the procedure.
Study: NCT00859573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: 400 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive substance
Study: NCT00653068

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous PBSC rescue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous PBSC rescue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV or SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV or SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT03577483

Intervention type: PROCEDURE
Group type: OTHER
Intervention: voice recordings
Description: A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: voice recordings
Description: A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice).
Study: NCT03244215

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance Imaging
Description: MRI will be ordered for all study subjects at the completion of their participation at year 1. The MRI will assess the the progression or regression of the cerebrovascular health of the study subjects.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood samples will be obtained to evaluate the levels of blood inflammatory biomarkers in both the subjects and control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood samples will be obtained to evaluate the levels of blood inflammatory biomarkers in both the subjects and control group.
Study: NCT04960501

Intervention type: PROCEDURE
Intervention: New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella
Description: New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella

Intervention type: PROCEDURE
Intervention: New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella
Description: New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella
Study: NCT00888862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate
Description: Desvenlafaxine Succinate, 50-100mg/day for 8 weeks
Study: NCT02925494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/Norethindrone Acetate
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: film-coated tablets
Study: NCT03636061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC-01 (varenicline) nasal spray
Description: OC-01 (varenicline) nasal spray
Study: NCT00653068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT02180568

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipiodol
Description: Lipiodol-guided lung localization technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hookwire
Description: Hookwire-guided lung localization technique

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipiodol
Study: NCT01305941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: everolimus 5 mg PO daily as two 2.5-mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: vinorelbine 25 mg/m2 will be administered via IV infusion over 6-10 minutes weekly.
Study: NCT03636061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC-01 (varenicline) nasal spray
Description: OC-01 (varenicline) nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC-01 (varenicline) nasal spray
Description: OC-01 (varenicline) nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle) nasal spray
Description: Placebo
Study: NCT01927510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early mobilisation
Study: NCT01305941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 2 mg/kg IV administered over 30 minutes weekly
Study: NCT01683383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device (servo-regulated cooling)
Description: Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (standard practice)
Description: Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
Study: NCT01816386

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture Regimen
Description: Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press needles (with a sharp tip) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
Study: NCT02601378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXS196
Description: LXS196 as a single agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXS196 and HDM201
Description: LXS196 in combination with HDM201
Study: NCT00880009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 400mg (4x100)mg tablets once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
Study: NCT01816386

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupressure Regimen
Description: Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press plasters (with a blunt knob instead a sharp needle) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
Study: NCT01736163

Intervention type: DRUG
Intervention: Thyrogen
Description: 0.9 mg IM, administrated for 2 consecutive days

Intervention type: DRUG
Intervention: 131I
Description: 28 mCi or ≥ 1.036 GBq.

Intervention type: DRUG
Intervention: 131I
Description: 28 mCi or ≥ 1.036 GBq.

Intervention type: OTHER
Intervention: Thyroid Hormone Withdrawal
Description: Stop taking hormone therapy
Study: NCT01428986

Intervention type: DRUG
Intervention: Maraviroc
Description: Maraviroc, 300mg BID for 72 weeks, except for cases with Efavirenz or Etravirine, 600mg BID for 72 weeks
Study: NCT03556072

Intervention type: OTHER
Intervention: Routine ERCP

Intervention type: OTHER
Intervention: Routine ERCP
Study: NCT02469922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy
Description: Every patients will be treated with radiochemotherapy as a standard of care
Study: NCT01745133

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle foam
Description: clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcipotriene
Description: clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcipotriene + clobetasol propionate
Description: clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
Study: NCT03972332

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative Sensory Testing
Description: PPT: An electronic data collection unit will be used featuring an electronic algometer connected with a laptop where the amount of pressure will be displayed on the screen. When the pressure pain detection threshold is reached (the point where the pressure sensation starts to be experienced as pain), the individual will press a button at a handheld device, that will automatically store the pressure value in the system and serve as an indication, for the examiner, to stop the testing.~TS: A pinprick stimulator (Weight: 256mNewton) will be used. The examiner will apply the pen that features a retractable blunt needle in a repetitive manner (once per second for ten seconds). The individual will be asked for the intensity of pain (NRS) at the first and at the last time and the given score will be noted.~CPM: A manual blood pressure sphygmomanometer will be used in conjunction with the electronic algometer described above (PPT).

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative Sensory Testing
Description: PPT: An electronic data collection unit will be used featuring an electronic algometer connected with a laptop where the amount of pressure will be displayed on the screen. When the pressure pain detection threshold is reached (the point where the pressure sensation starts to be experienced as pain), the individual will press a button at a handheld device, that will automatically store the pressure value in the system and serve as an indication, for the examiner, to stop the testing.~TS: A pinprick stimulator (Weight: 256mNewton) will be used. The examiner will apply the pen that features a retractable blunt needle in a repetitive manner (once per second for ten seconds). The individual will be asked for the intensity of pain (NRS) at the first and at the last time and the given score will be noted.~CPM: A manual blood pressure sphygmomanometer will be used in conjunction with the electronic algometer described above (PPT).
Study: NCT02771093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trelagliptin
Description: Trelagliptin 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 25 mg tablet
Study: NCT01651247

Intervention type: PROCEDURE
Intervention: Serum sample
Description: Serum samples collected at pre-determined time points in previously completed studies (217744/085 and 213503/048) will be analysed to detect the presence of anti PCV-1 antibodies.

Intervention type: PROCEDURE
Intervention: Serum sample
Description: Serum samples collected at pre-determined time points in previously completed studies (217744/085 and 213503/048) will be analysed to detect the presence of anti PCV-1 antibodies.
Study: NCT00681005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabeprazole
Description: 20 mg bid for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole
Description: pantoprazole 40 mg bid
Study: NCT00291577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib (Sutent)
Description: Sunitinib (Sutent) 37.5 mg in schedule 2/1; Sunitinib (Sutent) 37.5 mg in continuous dosing (post discontinuation of axotere) and in accordance with Investigator decision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Taxotere 75 mg/m2 iv, once every 3 weeks